Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CNTX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | MPM BioImpact LLC | 1.30M | 1.4% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Blue Owl Capital Holdings LP | 2.93M | 3.2% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Ting Jia | 3.05M | 3.3% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Octagon Investments Master Fund LP | 3.05M | 3.3% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Octagon Capital Advisors LP | 3.05M | 3.3% | SCHEDULE 13G/A ↗ |
| Jul 27, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | BlackRock, Inc. | 6.17M | 6.7% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Ms. Lillian Nordahl | 2.24M | 2.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Dr. Jeffrey R. Jay, M.D. | 2.24M | 2.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Great Point Partners, LLC | 2.24M | 2.4% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Ting Jia | 5.25M | 5.7% | SCHEDULE 13G ↗ |
| May 14, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Octagon Investments Master Fund LP | 5.25M | 5.7% | SCHEDULE 13G ↗ |
| May 14, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Octagon Capital Advisors LP | 5.25M | 5.7% | SCHEDULE 13G ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Blue Owl Capital Holdings LP | 5.09M | 5.5% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Michael Gregory | 8.30M | 8.7% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Private Master Fund I LP | 7.36M | 7.7% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Capital Partners (GP) LLC | 8.30M | 8.7% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Capital Partners Fund (GP) LP | 8.30M | 8.7% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Partners Management (GP) LLC | 8.30M | 8.7% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Partners Management LP | 8.30M | 8.7% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Guy Levy | 6.96M | 7.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Soleus GP, LLC | 6.96M | 7.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Soleus Capital Management, L.P. | 6.96M | 7.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Soleus Capital Group, LLC | 6.96M | 7.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Soleus Capital, LLC | 6.96M | 7.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Soleus Capital Master Fund, L.P. | 6.96M | 7.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | MPM BioImpact LLC | 10.68M | 11.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Ms. Lillian Nordahl | 4.68M | 5.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Dr. Jeffrey R. Jay, M.D. | 4.68M | 5.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Great Point Partners, LLC | 4.68M | 5.1% | SCHEDULE 13G/A ↗ |
| Feb 3, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Guy Levy | 4.78M | 5.2% | SCHEDULE 13G ↗ |
| Feb 3, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Soleus GP, LLC | 4.78M | 5.2% | SCHEDULE 13G ↗ |
| Feb 3, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Soleus Capital Management, L.P. | 4.78M | 5.2% | SCHEDULE 13G ↗ |
| Feb 3, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Soleus Capital Group, LLC | 4.78M | 5.2% | SCHEDULE 13G ↗ |
| Feb 3, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Soleus Capital, LLC | 4.78M | 5.2% | SCHEDULE 13G ↗ |
| Feb 3, 2026 | SCHEDULE 13G | CNTX Context Therapeutics Inc. | Soleus Capital Master Fund, L.P. | 4.78M | 5.2% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Ms. Lillian Nordahl | 4.68M | 5.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Dr. Jeffrey R. Jay, M.D. | 4.68M | 5.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Great Point Partners, LLC | 4.68M | 5.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Michael Gregory | 9.20M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Private Master Fund I LP | 7.78M | 8.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Private Master Fund I LP | 7.78M | 8.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Master Fund LP | 4.51M | 4.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Capital Partners (GP) LLC | 9.20M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Capital Partners Fund (GP) LP | 9.20M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Partners Management (GP) LLC | 9.20M | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Avidity Partners Management LP | 9.20M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Ms. Lillian Nordahl | 4.68M | 5.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Dr. Jeffrey R. Jay, M.D. | 4.68M | 5.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Great Point Partners, LLC | 4.68M | 5.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | CNTX Context Therapeutics Inc. | Michael Gregory | 9.13M | 9.9% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances